Domenico Mallardo

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Mariaelena Capone, Diana Giannarelli, Domenico Mallardo et al. · Journal for ImmunoTherapy of Cancer · 2018 · 511 citations · Full text

Medicine, Immunology, Oncology +17

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

Clélia Coutzac, Jean-Mehdi Jouniaux, Angélo Paci et al. · Nature Communications · 2020 · 469 citations · Full text

Life Sciences, Immunology, Oncology +17

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Alessio Cortellini, Marco Tucci, Vincenzo Adamo et al. · Journal for ImmunoTherapy of Cancer · 2020 · 264 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci et al. · Journal of Clinical Oncology · 2022 · 220 citations

Pharmacy, Oncology, Pharmacotherapy +17

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Caroline A. Nebhan, Alessio Cortellini, Weijie Ma et al. · JAMA Oncology · 2021 · 152 citations · Full text

Medicine, Immunology, Oncology +17